American Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program

US 29 May 2020 - 31 May 2020

What drives COVID-19 mortality in cancer?

06 Aug 2020 by

Among patients with cancer who develop COVID-19, progressive disease and a higher ECOG* performance status (PS) are tied to an increased risk of mortality, according to early results ascertained from the COVID-19 and Cancer Consortium (CCC19) registry.

What drives COVID-19 mortality in cancer?

06 Aug 2020

Pembrolizumab yields PFS benefits over brentuximab vedotin in R/R classical Hodgkin lymphoma

15 Jul 2020 by

Pembrolizumab may extend progression-free survival (PFS) in patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) who are ineligible for or have relapsed following autologous stem-cell transplant (auto-SCT), according to the phase III KEYNOTE-204 trial.

Pembrolizumab yields PFS benefits over brentuximab vedotin in R/R classical Hodgkin lymphoma

15 Jul 2020

Enzalutamide-ADT extends OS in nmCRPC

13 Jul 2020 by

The addition of enzalutamide to androgen deprivation therapy (ADT) improved overall survival (OS) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC), demonstrated the phase III PROSPER* trial.

Enzalutamide-ADT extends OS in nmCRPC

13 Jul 2020

Global registry links treatments to death in thoracic cancer patients with COVID-19

13 Jul 2020 by

Prior treatment with chemotherapy alone, chemotherapy plus immunotherapy, steroids or anticoagulants is associated with an increased risk of death in patients with thoracic cancer who develop coronavirus disease 2019 (COVID-19), new data from the global TERAVOLT (Thoracic Cancers International COVID-10 Collaboration) registry have shown.

Global registry links treatments to death in thoracic cancer patients with COVID-19

13 Jul 2020

Vitamin D protective against advanced cancer?

09 Jul 2020 by

Vitamin D supplementation can reduce the incidence of advanced cancer among older adults, in particular those with a normal BMI but not those who are overweight or obese, suggests the large VITAL* randomized study presented during the ASCO 2020 Meeting.

Vitamin D protective against advanced cancer?

09 Jul 2020

Smoking cessation improves lung cancer survival

05 Jul 2020 by

Quitting smoking as recently as 2 years prior to lung cancer diagnosis may improve survival, according to a study from ASCO20.

Smoking cessation improves lung cancer survival

05 Jul 2020

JAVELIN ushers paradigm shifts in maintenance for advanced bladder cancer

02 Jul 2020 by

Adding the PD-L1 inhibitor avelumab to best supportive care in the maintenance setting yields significant survival benefit compared with best supporting care alone for patients with advanced bladder cancer who have stable disease following first-line platinum-based chemotherapy, an interim analysis of the JAVELIN Bladder 100 study shows.

JAVELIN ushers paradigm shifts in maintenance for advanced bladder cancer

02 Jul 2020

Pembrolizumab + chemo improves PFS in previously untreated, advanced TNBC

02 Jul 2020 by

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.

Pembrolizumab + chemo improves PFS in previously untreated, advanced TNBC

02 Jul 2020

Longer imatinib use confers survival benefit for GI stromal tumours

30 Jun 2020 by

Three years of adjuvant imatinib treatment is superior in efficacy vs 1-year use in patients with gastrointestinal stromal tumours (GIST) at high risk of recurrence post-surgery, according to the secondary analysis of the SSGXVIII/AIO* trial.

Longer imatinib use confers survival benefit for GI stromal tumours

30 Jun 2020

Pembrolizumab + axitinib benefit sustained at 24 months for advanced RCC

24 Jun 2020 by

The combination therapy of pembrolizumab + axitinib continued to demonstrate significant improvements in overall survival (OS) and progression-free survival (PFS) among patients with advanced renal cell carcinoma (RCC) over an extended 24-month follow-up, according to the KEYNOTE-426* study presented at ASCO20 Virtual Scientific Program.

Pembrolizumab + axitinib benefit sustained at 24 months for advanced RCC

24 Jun 2020